₹26665.0
-0.07% today
· 30d +2.76%
as of 2026-11-09
Price · Daily Candles
“Abbott India's growth persists, but valuation stretches amidst fluctuating FII interest.”
Abbott India reported a healthy 17.75% YoY net profit growth and 9.76% YoY revenue growth for the period ending March 2025. Despite recent share price declines of 10.5% over the past year, the stock trades at a high PE of 37.75, compared to some peers below 30.
BULL CASE
+Annual net profit surged by 17.75% YoY to ₹1414 Cr for the period ending March 2025, with revenue up 9.76% to ₹6721 Cr.
+The 3-year CAGR for net profit stands strong at 20.99%, coupled with a 10.39% revenue CAGR.
+ROE is robust at 33.41% and the company maintains a low debt-to-equity ratio of 0.05.
+ML sales growth prediction (1yr, recent 2yr) is strong, with a rank of 0.801.
BEAR CASE
−The stock is down 10.5% over the past year and 6.52% in the last 6 months, currently trading 25.39% below its 52-week high of ₹37000.
−Abbott India trades at a PE of 37.75, notably higher than peers like CIPLA (29.52) and DRREDDY (19.55).
−FII shareholding decreased by 0.09% QoQ, despite DIIs increasing their stake by 0.26%.
⟳ What Changed
◇ Sector Position
Trading at a PE of 37.75 and an ROE of 33.41%, Abbott India commands a higher valuation than peers like CIPLA (PE 29.52, ROCE 25.09%) and DRREDDY (PE 19.55, ROCE 27.63%).
PEERPEROCE %
ABBOTINDIA37.75—
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
67
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
NEUTRAL
40
Valuation
FAIR
40
Growth
STEADY
63
Profitability
HIGH
100
Technicals
NEUTRAL
65
Risk
LOW
92
Key Stats
TTM PE
37.75
P/B
12.29
52W HIGH
₹30655.0
OFF HIGH
-13.02%
DIV YIELD
1.89%
MKT CAP
₹56672 Cr
◉ Active Signals
MACDBullish126.856
RSI(14)Neutral56.36
Near 52W LowBearish8.17
Street Consensus
8 analysts₹32563.38
mean target
Low ₹27500.0Now ₹26665.0High ₹38100.0
⧉ Strategy Fit 🔒